Fulcrum Therapeutics begins trial of muscle disorder drug for COVID-19 patients

Fulcrum Therapeutics Inc said on Wednesday it has started the late-stage trial of its experimental muscle disorder drug, losmapimod, in high-risk hospitalized adults tested positive for COVID-19.

The company expects to report topline data in the first quarter of 2021.

Fulcrum said it had exclusively in-licensed losmapimod from GlaxoSmithKline PLC last year.